Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

✍ Scribed by Peshwa, Madhusudan V.; Shi, Jia Dong; Ruegg, Curtis; Laus, Reiner; van Schooten, Wim C.A.

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 195 KB
• Volume: 36
• Category: Article
• ISSN: 0270-4137
• DOI: 10.1002/(sici)1097-0045(19980701)36:2<129::aid-pros8>3.0.co;2-d

✦ Synopsis

BACKGROUND.

Most strategies in cancer immunotherapy are aimed at the induction of a strong cellular immune response against the tumor. Particularly, CD8 + T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors. METHODS. We used a population of peripheral blood-derived antigen-presenting cells (APC), containing dendritic cells (DC), to generate prostate tumor-specific CD8 + T cells. Selected peptides from prostatic acid phosphatase (PAP), a prostate tissue-specific antigen, were shown to bind HLA-A2. A high-affinity peptide was used to generate peptide-specific CD8 + cytolytic T lymphocytes (CTL) from the peripheral blood of healthy donors. RESULTS. The obtained PAP-peptide-specific CTL lysed peptide-coated target cells, vaccinia-infected target cells, and HLA-A2-positive prostate-tumor cells in vitro in an antigenspecific manner. CONCLUSIONS. Our results indicate that CTL precursors to the PAP gene product exist and could be potentially recruited to elicit an antitumor response. Thus, PAP is a suitable antigen for inclusion in prostate cancer vaccines.